Over the years, there has been neglect of kala azar by pharmaceutical companies as well as funding agencies because the affected do not have purchasing power, said Monique Wasunna, assistant research director at the Kenya Medical Research Institute and Africa head of the Drugs for Neglected Diseases initiative (DNDi) [ http://www.dndi.org/ ].